Addition of low dose acetazolamide as an adjunct in patients undergoing high dose methotrexate is safe and beneficial.

AZL appeared to diminish the incidence of HDMTx-induced toxicities, including reducing oedema-related weight gain. With mild, preventable hypokalaemia as the only noteworthy toxicity, AZL could be considered as an adjunct to HDMTx patient care.